SIRT4
Basic information
Region (hg38): 12:120302316-120313249
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SIRT4 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 1 | |||||
missense | 22 | 25 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 0 | 0 | 22 | 2 | 2 |
Variants in SIRT4
This is a list of pathogenic ClinVar variants found in the SIRT4 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
12-120303624-C-G | not specified | Uncertain significance (Oct 10, 2023) | ||
12-120303647-T-C | not specified | Likely benign (May 16, 2024) | ||
12-120303767-C-T | not specified | Uncertain significance (Sep 12, 2023) | ||
12-120303812-G-T | not specified | Uncertain significance (Oct 26, 2021) | ||
12-120303850-C-T | not specified | Uncertain significance (Jun 02, 2023) | ||
12-120303865-C-T | Benign (Mar 02, 2018) | |||
12-120303866-G-A | not specified | Uncertain significance (Jun 24, 2022) | ||
12-120303881-C-T | not specified | Uncertain significance (Nov 15, 2021) | ||
12-120303955-G-A | not specified | Uncertain significance (Oct 12, 2021) | ||
12-120303964-G-A | not specified | Uncertain significance (Dec 06, 2022) | ||
12-120304016-C-T | not specified | Uncertain significance (Jul 26, 2022) | ||
12-120304025-G-A | not specified | Likely benign (Jan 10, 2023) | ||
12-120304052-T-A | not specified | Uncertain significance (Jun 24, 2022) | ||
12-120312472-T-G | not specified | Uncertain significance (Mar 04, 2024) | ||
12-120312482-A-C | not specified | Uncertain significance (Dec 02, 2022) | ||
12-120312508-C-T | not specified | Uncertain significance (Mar 01, 2023) | ||
12-120312571-G-A | Likely benign (Dec 01, 2022) | |||
12-120312577-C-G | not specified | Uncertain significance (Aug 13, 2021) | ||
12-120312648-T-G | not specified | Uncertain significance (Mar 07, 2023) | ||
12-120312713-A-C | not specified | Uncertain significance (May 24, 2023) | ||
12-120312718-G-A | not specified | Uncertain significance (May 29, 2024) | ||
12-120312897-A-C | not specified | Uncertain significance (May 30, 2023) | ||
12-120312926-A-C | not specified | Uncertain significance (Sep 22, 2022) | ||
12-120312936-T-C | not specified | Uncertain significance (Sep 26, 2023) | ||
12-120312943-A-T | Benign (Mar 02, 2018) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
SIRT4 | protein_coding | protein_coding | ENST00000202967 | 3 | 10934 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
6.86e-10 | 0.0389 | 125691 | 0 | 56 | 125747 | 0.000223 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.01 | 158 | 198 | 0.797 | 0.0000124 | 2033 |
Missense in Polyphen | 58 | 73.518 | 0.78892 | 759 | ||
Synonymous | 0.816 | 69 | 78.2 | 0.883 | 0.00000475 | 652 |
Loss of Function | -0.518 | 13 | 11.1 | 1.17 | 4.74e-7 | 129 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000662 | 0.000662 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000435 | 0.000435 |
Finnish | 0.0000462 | 0.0000462 |
European (Non-Finnish) | 0.0000969 | 0.0000967 |
Middle Eastern | 0.000435 | 0.000435 |
South Asian | 0.000653 | 0.000653 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Acts as NAD-dependent protein lipoamidase, ADP-ribosyl transferase and deacetylase. Catalyzes more efficiently removal of lipoyl- and biotinyl- than acetyl-lysine modifications. Inhibits the pyruvate dehydrogenase complex (PDH) activity via the enzymatic hydrolysis of the lipoamide cofactor from the E2 component, DLAT, in a phosphorylation-independent manner (PubMed:25525879). Catalyzes the transfer of ADP-ribosyl groups onto target proteins, including mitochondrial GLUD1, inhibiting GLUD1 enzyme activity. Acts as a negative regulator of mitochondrial glutamine metabolism by mediating mono ADP- ribosylation of GLUD1: expressed in response to DNA damage and negatively regulates anaplerosis by inhibiting GLUD1, leading to block metabolism of glutamine into tricarboxylic acid cycle and promoting cell cycle arrest (PubMed:16959573, PubMed:17715127). In response to mTORC1 signal, SIRT4 expression is repressed, promoting anaplerosis and cell proliferation. Acts as a tumor suppressor (PubMed:23562301, PubMed:23663782). Also acts as a NAD- dependent protein deacetylase: mediates deacetylation of 'Lys-471' of MLYCD, inhibiting its activity, thereby acting as a regulator of lipid homeostasis (By similarity). Does not seem to deacetylate PC (PubMed:23438705). Controls fatty acid oxidation by inhibiting PPARA transcriptional activation. Impairs SIRT1:PPARA interaction probably through the regulation of NAD(+) levels (PubMed:24043310). Down-regulates insulin secretion. {ECO:0000255|HAMAP-Rule:MF_03161, ECO:0000269|PubMed:16959573, ECO:0000269|PubMed:17715127, ECO:0000269|PubMed:23438705, ECO:0000269|PubMed:23562301, ECO:0000269|PubMed:23663782, ECO:0000269|PubMed:24043310, ECO:0000269|PubMed:25525879}.;
- Pathway
- NAD+ metabolism;NAD+ biosynthetic pathways;Transcriptional activation of mitochondrial biogenesis;Mitochondrial biogenesis;Organelle biogenesis and maintenance
(Consensus)
Intolerance Scores
- loftool
- 0.968
- rvis_EVS
- -0.09
- rvis_percentile_EVS
- 46.92
Haploinsufficiency Scores
- pHI
- 0.150
- hipred
- N
- hipred_score
- 0.255
- ghis
- 0.483
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.931
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Sirt4
- Phenotype
- homeostasis/metabolism phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); normal phenotype; skeleton phenotype;
Gene ontology
- Biological process
- regulation of glutamine family amino acid metabolic process;chromatin silencing;protein ADP-ribosylation;glutamine metabolic process;cellular response to DNA damage stimulus;mitochondrion organization;negative regulation of cardiac muscle cell apoptotic process;peptidyl-lysine deacetylation;negative regulation of fatty acid oxidation;negative regulation of insulin secretion;positive regulation of lipid biosynthetic process;cellular response to hypoxia;tricarboxylic acid metabolic process;negative regulation of protein processing involved in protein targeting to mitochondrion;regulation of pyruvate dehydrogenase activity
- Cellular component
- mitochondrion;mitochondrial inner membrane;mitochondrial matrix
- Molecular function
- NAD+ ADP-ribosyltransferase activity;protein binding;zinc ion binding;NAD-dependent protein deacetylase activity;biotinidase activity;lipoamidase activity;NAD+ binding